PIK-ORL: A phase II, multicenter trial aiming to evaluate BKM120 in monotherapy in patients (pts) with metastatic/recurrent head and neck squamous cell carcinoma (HNSCC) after failure of platin and cetuximab or anti-EGFR-based therapy

Authors :: L. Jaouen
Gwenaelle Garin
M. Matias
Caroline Even
J. Fayette
Qing Wang
Isabelle Treilleux
Audrey Mailliez
Sophie Tartas
L. Digue
C. Le Tourneau
Aurélie Guyennon
Sophie Couchon-Thaunat
Celine Ferlay
M. Degardin
D. Perol
G. Lefebvre
Gilles Clapisson
C. Hebert
Didier Cupissol
Source :: Annals of Oncology. 27:vi331
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: 0301 basic medicine
Oncology
medicine.medical_specialty
Metastatic/Recurrent
Cetuximab
business.industry
Hematology
medicine.disease
Head and neck squamous-cell carcinoma
03 medical and health sciences
030104 developmental biology
Multicenter trial
Internal medicine
medicine
In patient
business
medicine.drug

Full Text Access

Tools